Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial

• Published in: Clinical orthopaedics and related research 2023-08, Vol.481 (8), p.1527-1540
• Main Authors: Jayankura, Marc, Thomas, Thierry, Seefried, Lothar, Dubrana, Frederic, Günther, Klaus-Peter, Rondia, Jean, Davis, Edward T., Winnock de Grave, Philip, Carron, Philippe, Gangji, Valérie, Vande Berg, Bruno, Godeaux, Olivier, Sonnet, Wendy
• Format: Article
• Language: English
• Subjects: Adult; Adverse events; Autografts; Bone marrow; Clinical Research; Clinical trials; Decompression; Decompression, Surgical - adverse effects; Decompression, Surgical - methods; Double-Blind Method; Double-blind studies; Female; Femur; Femur Head - surgery; Femur Head Necrosis - diagnostic imaging; Femur Head Necrosis - surgery; Fractures; Humans; Male; Necrosis; Osteoblasts; Osteonecrosis; Pain; Patients; Placebos; Radiography; Transplantation; Treatment Outcome
• ISSN: 0009-921X; 1528-1132; 1528-1132
• DOI: 10.1097/CORR.0000000000002610

Osteonecrosis of the femoral head (ONFH) is a disabling disease that can ultimately progress to collapse of the femoral head, often resulting in THA. Core decompression of the femoral head combined with cell therapies have shown beneficial effects in previous clinical studies in patients with early-stage (Association Research Circulation Osseous [ARCO] Stage I and II) ONFH. However, high-quality evidence confirming the efficacy of this treatment modality is still lacking. (1) Is core decompression combined with autologous osteoblastic cell transplantation superior to core decompression with placebo implantation in relieving disease-associated pain and preventing radiologic ONFH progression in patients with nontraumatic early-stage ONFH? (2) What adverse events occurred in the treatment and control groups? This study was a Phase III, multicenter, randomized, double-blind, controlled study conducted from 2011 to 2019 (ClinicalTrails.gov registry number: NCT01529008). Adult patients with ARCO Stage I and II ONFH were randomized (1:1) to receive either core decompression with osteoblastic cell transplantation (5 mL with 20 x 10 6 cells/mL in the study group) or core decompression with placebo (5 mL of solution without cells in the control group) implantation. Thirty percent (68 of 230) of the screened patients were eligible for inclusion in the study; of these, 94% (64 of 68) underwent a bone marrow harvest or sham procedure (extended safety set) and 79% (54 of 68) were treated (study group: 25 patients; control group: 29). Forty-nine patients were included in the efficacy analyses. Similar proportions of patients in each group completed the study at 24 months of follow-up (study group: 44% [11 of 25]; control: 41% [12 of 29]). The study and control groups were comparable in important ways; for example, in the study and control groups, most patients were men (79% [27 of 34] and 87% [26 of 30], respectively) and had ARCO Stage II ONFH (76% [19 of 25] and 83% [24 of 29], respectively); the mean age was 46 and 45 years in the study and control groups, respectively. The follow-up period was 24 months post-treatment. The primary efficacy endpoint was the composite treatment response at 24 months, comprising the clinical response (clinically important improvement in pain from baseline using the WOMAC VA3.1 pain subscale, defined as 10 mm on a 100-mm scale) and radiologic response (the absence of progression to fracture stage [≥ ARCO Stage III], as assessed by conven